- Home
- Fund
- Angel / Venture
- ImmPACT Bio Closes $111 Million Series B…
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Most Popular
Recent Posts
- Ravencoin Mining Economics September 5, 2023
- KKR to Present at the Bernstein 39th Annual Strategic Decisions Conference 2023 July 6, 2023
- Restaurant365 Announces $135M Funding Round Co-Led by KKR and L Catterton July 6, 2023
- KKR Names Dan Pietrzak Global Head of Private Credit July 6, 2023
- KREST Names Julia Butler As Chief Investment Officer July 6, 2023